Biotechnology News and Research

RSS

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease.

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Biological scientists lead major research project that aims to make drugs more effective

University of Southampton biological scientists are leading a major research project aimed at making drugs more effective.

27 Mar 2013

Roundup: Report finds Mass. biotech spending creates jobs; Federal audit calls for N.Y. Medicaid program to repay funds

News outlets report on health care developments in California, Colorado, Georgia, Massachusetts, New York, North Carolina and Texas.

27 Mar 2013

Genalyte's Maverick Detection System gets CE mark in Europe for research use

Genalyte, Inc. today announced its Maverick Detection System that simultaneously analyzes multiple antibodies and other proteins from a single small sample is now CE marked in Europe for research use.

26 Mar 2013

Two researchers awarded grants to develop indicators, biomarkers for dementia with Lewy bodies

The Lewy Body Dementia Association and the Alzheimer's Drug Discovery Foundation have awarded $100,000 each to Omar El-Agnaf, PhD, of United Arab Amirates University and Michelle Mielke, PhD, of Mayo Clinic Rochester to provide one year of support for their research projects focused on developing indicators, or biomarkers, for dementia with Lewy bodies.

26 Mar 2013

Harvard scientists to further advance blood-cleansing technology for treating sepsis

The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that it was awarded a $9.25 million contract from the Defense Advanced Research Projects Agency to further advance a blood-cleansing technology developed at the Institute with prior DARPA support, and help accelerate its translation to humans as a new type of sepsis therapy.

26 Mar 2013

Calibr, JDRF partner to research on promising type 1 diabetes therapeutic targets

The California Institute for Biomedical Research and JDRF announced a partnership today to apply Calibr's drug discovery expertise to type 1 diabetes research projects in collaboration with academic investigators from JDRF's network.

25 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

LMU researchers identify microRNA that offers promising target for new therapies

Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. Researchers at Ludwig-Maximilians-Universitaet in Munich have now identified a microRNA that plays a prominent role in the process, and offers a promising target for new therapies.

25 Mar 2013

Autistic children's brains have reduced connectivity, diminished capacity for neural communication

A new study of patterns of brain communication in toddlers with autism shows evidence of aberrant neural communication even at this relatively early stage of brain development. The results are presented in an article in Brain Connectivity, a bimonthly peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

22 Mar 2013

Dysfunction of Calcium channel in neurons of cerebellum causes different motor diseases

A dysfunction of a certain Calcium channel, the so called P/Q-type channel, in neurons of the cerebellum is sufficient to cause different motor diseases as well as a special type of epilepsy.

22 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

Researchers develop promising drug candidate to treat psoriasis

Ben-Gurion University of the Negev researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis.

21 Mar 2013

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs.

21 Mar 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013

Biogen receives additional patent protection for MS drug TECFIDERA

Biogen Idec today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,399,514, which offers additional protection for TECFIDERA (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis.

20 Mar 2013

Rensselaer professor awarded NIH grant to explore cellular function with links to diverse diseases

The interior of every cell within our bodies is crisscrossed with a network of molecular highways upon which nutrients, replacement parts, and other vital materials travel to their appropriate location.

20 Mar 2013

Biotechnology News and Research

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Neurological researchers study promising new treatment for deadly brain tumors

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Biological scientists lead major research project that aims to make drugs more effective

Roundup: Report finds Mass. biotech spending creates jobs; Federal audit calls for N.Y. Medicaid program to repay funds

Genalyte's Maverick Detection System gets CE mark in Europe for research use

Two researchers awarded grants to develop indicators, biomarkers for dementia with Lewy bodies

Harvard scientists to further advance blood-cleansing technology for treating sepsis

Calibr, JDRF partner to research on promising type 1 diabetes therapeutic targets

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

LMU researchers identify microRNA that offers promising target for new therapies

Autistic children's brains have reduced connectivity, diminished capacity for neural communication

Dysfunction of Calcium channel in neurons of cerebellum causes different motor diseases

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

Researchers develop promising drug candidate to treat psoriasis

Combination of HUCBCs and Simvastatin offers promising therapy for stroke: Study

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

Biogen receives additional patent protection for MS drug TECFIDERA

Rensselaer professor awarded NIH grant to explore cellular function with links to diverse diseases

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News